SES AUA 2025: Phase 1 Trial of Mevrometostat (PF-06821497), a Potent and Selective Inhibitor of EZH2, in CRPC - UroToday
SES AUA 2025: Phase 1 Trial of Mevrometostat (PF-06821497), a Potent and Selective Inhibitor of EZH2, in CRPC UroToday ...
SES,AUA,2025:,Phase,1,Trial,of,Mevrometostat,(PF-06821497),